Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors

Inclusion Criteria:

- Adults 18 years of age or older

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy at least 12 weeks

- Adequate hematologic and end organ function

- Histologic documentation of locally advanced, recurrent, or metastatic incurable
malignancy that has progressed after at least one available standard therapy; or for
which standard therapy has proven ineffective, intolerable, or considered
inappropriate; or for which a clinical trial of an investigational agent is a
recognized standard of care

- Confirmed availability of representative tumor specimens

- Measurable disease according to RECIST Version 1.1

Exclusion Criteria:

- Any anti-cancer therapy, whether investigational or approved, including chemotherapy,
hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study
treatment

- Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1

- Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases

- Leptomeningeal disease

- History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or
evidence of active pneumonitis on Screening chest computed tomograph (CT) scan

- History of autoimmune disease

- Positive human immunodeficiency virus (HIV) test

- Active hepatitis B or C, or tuberculosis

- Severe infection within 4 weeks prior to randomization

- Prior allogeneic bone marrow or solid organ transplant

- Significant cardiovascular disease

- Known clinically significant liver disease